Focus: ADC Therapeutics is a specialized oncology biotech focused on antibody-drug conjugates (ADCs) for hematologic and solid tumors, currently generating revenue from a single approved product (ZYNLONTA) in the US market.
Profile data last refreshed 5h ago · AI intelligence enriched 2w ago
Growing — net +13 jobs in 30d
17 jobs added vs 4 removed. Steady team buildout.
Best suited for oncology specialists and commercial professionals betting on near-term Phase 3 catalysts and willing to accept high single-product risk for niche ADC expertise.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Only revenue-generating asset; peak-phase label represents current market penetration ceiling—critical to monitor real-world adoption trends.
Help build intelligence for ADC Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from ADC Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
ADC Therapeutics SA|Price:1.150|Chg%:-0.045 - TradingKey
ADC Therapeutics SA|Price:1.150|Chg%:-0.045 TradingKey
ADC Therapeutics stock stabilizes as Zynlonta revenue supports biotech valuation - Ad-hoc-news.de
ADC Therapeutics stock stabilizes as Zynlonta revenue supports biotech valuation Ad-hoc-news.de
ADC Therapeutics stock trades steady as revenue grows and liquidity plan develops - Ad-hoc-news.de
ADC Therapeutics stock trades steady as revenue grows and liquidity plan develops Ad-hoc-news.de
ADC Therapeutics updates trial strategy, shares react to oncology shift - AD HOC NEWS
ADC Therapeutics updates trial strategy, shares react to oncology shift AD HOC NEWS
Layoff Tracker: CLINUVEL will cut up to 20% of staff, relocate HQ to New York - BioSpace
Layoff Tracker: CLINUVEL will cut up to 20% of staff, relocate HQ to New York BioSpace
ADC Therapeutics cuts jobs as Zynlonta FDA talks loom - The Pharma Letter
ADC Therapeutics cuts jobs as Zynlonta FDA talks loom The Pharma Letter
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
+1 more
+2 more
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo